Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

Overview of attention for article published in OncoTargets and therapy, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy: 1 policy source
wikipedia: 1 Wikipedia page

reddit: 1 Redditor

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 29 Mendeley

Summary Policy documents Wikipedia Reddit Dimensions citations

So far, Dimensions has found 18 publications that cite this research output.

18

The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.

Efficacy and safety of crizotinib in the treatment of advanced non-small cell Lung cancer with ROS1 gene fusion: A systematic literature review and Meta-Analysis of real-world evidence

Article in Lung Cancer (May 2024)

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.

Article in Tumor Biology (January 2024)

Progress of non-small-cell lung cancer with ROS1 rearrangement

Article in Frontiers in Molecular Biosciences (December 2023)